[Bone-seeking behavior of rhenium and yttrium complexes]

Area of Science:

• Radiochemistry
• Biomedical research
• Pharmacokinetics

Background:

• Investigating bone-seeking radiopharmaceuticals is crucial for targeted therapies and diagnostics.
• Understanding the biodistribution of radioisotopes is essential for nuclear medicine applications.

Purpose of the Study:

• To evaluate the bone affinity of strontium (Sr) and yttrium (Y) citrate complexes.
• To assess the bone uptake and elimination of rhenium (Re) compounds.

Main Methods:

• Experimental administration of radiolabeled compounds (85SrCl2, 89SrCl2, 90Y citrate, 186Re perrhenate, 186Re-colloid, 186Re-MDP) to rats.
• Assessment of radioisotope distribution and elimination patterns.

Main Results:

• Strontium (85Sr, 89Sr) and yttrium (90Y) in citrate complexes exhibited significant accumulation in bone tissue.
• Rhenium (186Re) perrhenate, Re-colloid, and Re-methylene-diphosphonate were rapidly cleared from the body.
• 186Re compounds demonstrated minimal to no affinity for bone.

Conclusions:

• Citrate complexes of strontium and yttrium are promising candidates for bone-targeting radiopharmaceuticals.
• Rhenium-based compounds evaluated in this study are unsuitable for bone-seeking applications due to rapid elimination.